Vir Biotechnology, Inc 8-K, filed May 4, 2023
Vir Biotechnology, Inc. (VIR)
About this 8-K
Vir Biotechnology, Inc filed this 8-K on May 4, 2023.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On May 4, 2023, Vir Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits |
|
|
Exhibit No. |
|
Description |
99.1 |
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
VIR BIOTECHNOLOGY, INC. |
|
|
|
|
Date: |
May 4, 2023 |
By: |
/s/ Sung Lee |
|
|
|
Sung Lee |
Exhibit-99.1
Vir Biotechnology Provides Corporate Update and Reports
First Quarter 2023 Financial Results
– Multiple data readouts anticipated in 2023 from ongoing Phase 2 programs
in hepatitis B and D, and influenza –
– Industry veteran Dr. Marianne De Backer assumes CEO position prepared to lead Company through next phase of growth –
– $2.3 billion in cash, cash equivalents, and investments as of March 31, 2023 –
SAN FRANCISCO, MAY 4, 2023 – Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2023.
“Vir is at an exciting inflection point with three critical Phase 2 data readouts for hepatitis B, hepatitis D and influenza anticipated in the coming months,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer of Vir Biotechnology. “We believe that these near-term catalysts, together with the strength of our pipeline and balance sheet, position us well to continue bringing important new therapeutic options to patients worldwide and create long-term value.”
Pipeline Programs
Influenza
Hepatitis B Virus (HBV)
1
Hepatitis D Virus (HDV)
Human Immunodeficiency Virus (HIV)
COVID-19 (sotrovimab)
Corporate Update
2
First Quarter 2023 Financial Results
Revenues: Total revenues for the quarter ended March 31, 2023, were $63.0 million compared to $1.2 billion for the same period in 2022.
Revenues were comprised of the following components:
(in millions) |
Three months ended March 31
|
|
|
|
|
2023 |
2022 |
% Change |
|
Collaboration revenue |
$46.6 |
$1,229.7 |
(96.2%) |
|
Contract revenue |
0.1 |
0.3 |
(66.7%) |
|
Grant revenue |
16.2 |
2.5 |
> 100% |
|
Total revenues |
$63.0 |
$1,232.5 |
(94.9%) |
|
Note: Numbers may not add due to rounding |
||||
Cost of Revenue: Cost of revenue for the first quarter of 2023 was $1.9 million, compared to $90.1 million for the same period in 2022. The decrease was due to lower third-party royalties owed based on the sales of sotrovimab under the Company’s collaboration with GSK.
Research and Development Expenses (R&D): R&D expenses for the first quarter of 2023 were $157.6 million, which included $13.4 million of non-cash stock-based compensation expense, compared to $90.2 million for the same period in 2022, which included $13.1 million of non-cash stock-based compensation expense. The increase was primarily driven by higher investments to support the advancement of our clinical programs and in particular VIR-2482.
Selling, General and Administrative Expenses (SG&A): SG&A expenses for the first quarter of 2023 were $46.8 million, which included $12.1 million of non-cash stock-based compensation expense, compared to $38.3 million for the same period in 2022, which included $12.2 million of non-cash stock-based compensation expense. The increase was primarily due to higher headcount related costs.
Other Income (Expense): Other income for the first quarter of 2023 was $0.2 million compared to other expense of $91.9 million for the same period in 2022. The increase was primarily due to $95.0 million unrealized loss on equity investments recorded in the first quarter of 2022. The $0.2 million other income for the first quarter of 2023 consisted of $21.3 million of interest income, partially offset by $13.1 million unrealized loss on equity investments and $7.8 million unrealized foreign exchange losses.
3
Benefit from (Provision for) Income Taxes: Benefit from income taxes for the first quarter of 2023 was $2.2 million compared to ($403.3 million) provision for income taxes for the same period in 2022. The benefit from income taxes was primarily due to a pre-tax loss and our ability to carry-back the R&D credit to 2022.
Net (Loss) Income: Net loss attributable to Vir for the first quarter of 2023 was ($140.9 million), or ($1.06) per share, basic and diluted, compared to a net income attributable to Vir of $518.6 million, or $3.93 per share, basic and $3.85 per share, diluted for the same period in 2022.
Cash, Cash Equivalents, and Investments: As of March 31, 2023, the Company had approximately $2.3 billion in cash, cash equivalents, and investments. The Company anticipates a payment of approximately $272.1 million to GSK in the second quarter of 2023. This payment primarily relates to the amount reserved in 2022 for excess sotrovimab supply and manufacturing capacity and the subsequent reduced demand expectations for sotrovimab.
About VIR-2482
VIR-2482 is an investigational intramuscularly administered influenza A-neutralizing monoclonal antibody. In vitro, it has been shown to cover all major strains of influenza A that have arisen since the 1918 Spanish flu pandemic. VIR-2482 is designed as a prophylactic for influenza A. It has the potential to address the limitations of current flu vaccines and lead to meaningfully higher levels of protection due to its broad strain coverage and because it does not rely on an individual to create their own protective antibody response. VIR-2482, which incorporates Xencor’s Xtend™ technology, also has been half-life engineered so that a single dose has the potential to last the entire flu season. Under the collaboration agreement signed with GSK in 2021, GSK has an exclusive option to lead post-Phase 2 development and commercialization of VIR-2482.
The development of VIR-2482 has been supported in part with federal funds from the Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under Other Transaction Number: 75A50122C00081.
About VIR-2218
VIR-2218 is an investigational subcutaneously administered HBV-targeting siRNA that Vir believes has the potential to stimulate an effective immune response and have direct antiviral activity against HBV and HDV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially could result in an increased therapeutic index. VIR-2218 is the first asset in the Company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials.
About VIR-3434
VIR-3434 is an investigational subcutaneously administered antibody designed to block entry of hepatitis B and hepatitis D viruses into hepatocytes and to reduce the level of virions and subviral particles in the blood. VIR-3434, which incorporates Xencor’s Xtend™ and other Fc technologies, has been engineered to potentially function as a T cell vaccine against HBV and HDV in infected patients, as well as to have an extended half-life.
4
About VIR-1388
VIR-1388 is a preclinical subcutaneously administered HIV T cell vaccine based on HCMV that has been designed to elicit abundant T cells that recognize HIV epitopes in a way that differs from prior HIV vaccines.
About VIR-1111
VIR-1111 is an investigational subcutaneously administered HIV T cell vaccine based on HCMV that has been designed to elicit abundant T cells that recognize HIV epitopes in a way that differs from prior HIV vaccines.
About Sotrovimab
Sotrovimab is an investigational SARS-CoV-2 neutralizing monoclonal antibody. The antibody binds to an epitope on SARS-CoV-2 shared with SARS-CoV-1 (the virus that causes SARS). Sotrovimab, which incorporates Xencor, Inc.’s Xtend™️ technology, has been designed to achieve high concentration in the lungs to achieve optimal penetration into airway tissues affected by SARS-CoV-2 and to have an extended half-life. Sotrovimab is currently not authorized in the US.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, statements regarding Vir’s strategy and plans; Vir’s capital allocation; Vir’s future financial and operating results and its expectations related thereto; potential of, and expectations for, Vir’s pipeline; Vir’s clinical development programs, clinical trials, including the enrollment of Vir’s clinical trials, and data readouts and presentations; the potential benefits, safety, and efficacy of Vir’s investigational therapies; and risks and uncertainties associated with drug development and commercialization. Many important factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical trials or in data readouts; the timing and outcome of Vir’s planned interactions with regulatory authorities; difficulties in obtaining regulatory approval; uncertainty as to whether the anticipated benefits of Vir’s collaborations with other companies can be achieved; difficulties in collaborating with other companies; challenges in accessing manufacturing capacity; clinical site activation rates or clinical trial enrollment rates that are lower than expected; successful development and/or commercialization of alternative product candidates by Vir’s competitors; changes in expected or existing competition; delays in or disruptions to Vir’s business or clinical trials, geopolitical changes or other external factors; and unexpected litigation or other disputes. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from
5
later-stage or larger-scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the US Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Contact:
Carly Scaduto
Senior Director, Media Relations
cscaduto@vir.bio
+1-314-368-5189
6
Vir Biotechnology, Inc.
Condensed Consolidated Statements of Operations
(unaudited; in thousands, except share and per share data)
|
|
Three Months Ended March 31, |
|
|||||
|
|
2023 |
|
|
2022 |
|
||
Revenue: |
|
|
|
|
|
|
||
Collaboration revenue |
|
$ |
46,574 |
|
|
$ |
1,229,656 |
|
Contract revenue |
|
|
138 |
|
|
|
282 |
|
Grant revenue |
|
|
16,245 |
|
|
|
2,521 |
|
Total revenue |
|
|
62,957 |
|
|
|
1,232,459 |
|
Operating expenses: |
|
|
|
|
|
|
||
Cost of revenue |
|
|
1,907 |
|
|
|
90,149 |
|
Research and development |
|
|
157,643 |
|
|
|
90,227 |
|
Selling, general and administrative |
|
|
46,778 |
|
|
|
38,255 |
|
Total operating expenses |
|
|
206,328 |
|
|
|
218,631 |
|
(Loss) income from operations |
|
|
(143,371 |
) |
|
|
1,013,828 |
|
Other income (expense): |
|
|
|
|
|
|
||
Change in fair value of equity investments |
|
|
(13,103 |
) |
|
|
(95,039 |
) |
Interest income |
|
|
21,307 |
|
|
|
388 |
|
Other (expense) income, net |
|
|
(8,021 |
) |
|
|
2,730 |
|
Total other income (expense) |
|
|
183 |
|
|
|
(91,921 |
) |
(Loss) income before benefit from (provision for) income taxes |
|
|
(143,188 |
) |
|
|
921,907 |
|
Benefit from (provision for) income taxes |
|
|
2,232 |
|
|
|
(403,286 |
) |
Net (loss) income |
|
$ |
(140,956 |
) |
|
$ |
518,621 |
|
Net loss attributable to noncontrolling interest |
|
$ |
(56 |
) |
|
$ |
— |
|
Net (loss) income attributable to Vir |
|
$ |
(140,900 |
) |
|
$ |
518,621 |
|
Net (loss) income per share attributable to Vir, basic |
|
$ |
(1.06 |
) |
|
$ |
3.93 |
|
Net (loss) income per share attributable to Vir, diluted |
|
$ |
(1.06 |
) |
|
$ |
3.85 |
|
Weighted-average shares outstanding, basic |
|
|
133,552,839 |
|
|
|
132,079,391 |
|
Weighted-average shares outstanding, diluted |
|
|
133,552,839 |
|
|
|
134,535,766 |
|
7
Vir Biotechnology, Inc.
Condensed Consolidated Balance Sheets
(unaudited; in thousands, except share and per share data)
|
|
March 31, |
|
|
December 31, |
|
||
ASSETS |
|
|
|
|
|
|
||
CURRENT ASSETS: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
824,913 |
|
|
$ |
848,631 |
|
Short-term investments |
|
|
1,406,579 |
|
|
|
1,521,517 |
|
Restricted cash and cash equivalents, current |
|
|
10,957 |
|
|
|
12,681 |
|
Equity investments |
|
|
18,583 |
|
|
|
31,892 |
|
Prepaid expenses and other current assets |
|
|
97,602 |
|
|
|
104,356 |
|
Total current assets |
|
|
2,358,634 |
|
|
|
2,519,077 |
|
Intangible assets, net |
|
|
32,622 |
|
|
|
32,755 |
|
Goodwill |
|
|
16,937 |
|
|
|
16,937 |
|
Property and equipment, net |
|
|
103,758 |
|
|
|
105,609 |
|
Operating right-of-use assets |
|
|
81,505 |
|
|
|
82,557 |
|
Restricted cash and cash equivalents, noncurrent |
|
|
6,739 |
|
|
|
6,656 |
|
Long-term investments |
|
|
49,187 |
|
|
|
23,927 |
|
Other assets |
|
|
16,554 |
|
|
|
14,570 |
|
TOTAL ASSETS |
|
$ |
2,665,936 |
|
|
$ |
2,802,088 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
||
CURRENT LIABILITIES: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
12,149 |
|
|
$ |
6,422 |
|
Accrued and other liabilities |
|
|
455,922 |
|
|
|
489,090 |
|
Deferred revenue, current portion |
|
|
17,217 |
|
|
|
15,517 |
|
Total current liabilities |
|
|
485,288 |
|
|
|
511,029 |
|
Deferred revenue, noncurrent |
|
|
53,207 |
|
|
|
53,207 |
|
Operating lease liabilities, noncurrent |
|
|
121,461 |
|
|
|
123,837 |
|
Contingent consideration, noncurrent |
|
|
23,691 |
|
|
|
24,937 |
|
Deferred tax liability |
|
|
3,253 |
|
|
|
3,253 |
|
Other long-term liabilities |
|
|
8,235 |
|
|
|
7,862 |
|
TOTAL LIABILITIES |
|
|
695,135 |
|
|
|
724,125 |
|
STOCKHOLDERS’ EQUITY: |
|
|
|
|
|
|
||
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2023 and December 31, 2022; no shares issued and outstanding as of March 31, 2023 and December 31, 2022 |
|
|
— |
|
|
|
— |
|
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 133,930,957 and 133,236,687 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively |
|
|
13 |
|
|
|
13 |
|
Additional paid-in capital |
|
|
1,737,626 |
|
|
|
1,709,835 |
|
Accumulated other comprehensive loss |
|
|
(3,219 |
) |
|
|
(9,122 |
) |
Retained earnings |
|
|
236,337 |
|
|
|
377,237 |
|
Total Vir stockholder's equity |
|
|
1,970,757 |
|
|
|
2,077,963 |
|
Noncontrolling interest |
|
|
44 |
|
|
|
— |
|
TOTAL STOCKHOLDERS’ EQUITY |
|
|
1,970,801 |
|
|
|
2,077,963 |
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
$ |
2,665,936 |
|
|
$ |
2,802,088 |
|
8